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Abstract. 
 
The development of novel in vitro methods to assess risks of allergic sensitization are 
essential in reducing animal testing whilst maintaining consumer safety. The main research 
objectives of this study were to identify novel biomarkers to assess the sensitization 
predictability of chemicals. Phenotypic and cytokine responses of moDCs and MUTZ-3 cells 
were investigated following application of contact sensitizers; Dinitrochlorobenzene 
(DNCB), Cinnamaldehyde (Cin), Eugenol (E), Isoeugenol (IE), P- Phenylenediamine (PPD) 
and non-sensitizers; Salicyclic Acid (SA) and Sodium Lauryl Sulphate (SLS). CD86 was up-
regulated on MUTZ-3 cells in response to DNCB, Cin and PPD, however, moDCs only 
modulated CD86 in response to DNCB and E. PDL-1 (Programmed death receptor ligand-1) 
proved a promising sensitization biomarker in MUTZ-3 cells where up-regulation occurred in 
response to DNCB, Cin, IE and PPD. Additionally, moDC-expressed PDL-1 was modulated 
in response to Cin, IE and E thus demonstrating improved sensitizer predictability when 
compared with CD86. MCP-1 and RANTES were identified as biomarkers of DNCB 
exposure but MCP-1 did not show any change in expression above controls for the other 
sensitizers investigated. However, RANTES was increased in MUTZ-3 cells by both DNCB 
and Cin. Our findings highlight novel biomarkers which, in MUTZ-3 cells, could be taken 
forward within a multiple biomarker in vitro assay ensuring strong and reliable predictability.  
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1. Introduction. 
 
Dendritic cells (DCs) form a sentinel network and are specialised for the uptake, transport, 
processing and presentation of antigens to T cells. It is well established that DCs play an 
essential role in antigen recognition and priming of naive T cells in the initial phase of the 
sensitization reaction (Sasaki and Aiba, 2007). Allergic contact dermatitis (ACD) represents 
the clinical manifestation of a T cell mediated inflammatory reaction occurring in sensitized 
individuals upon allergen challenge. The mechanism of ACD sensitization occurs in two 
phases which firstly comprises sensitization, occurring upon first contact with the sensitizer 
and is subsequently followed by an elicitation phase upon secondary exposure to the 
sensitizer resulting in clinical manifestation of eczematous symptoms (Python et al., 2007).  
A European Union ban on in vivo testing of cosmetic and toiletry ingredients will be enforced 
in 2013, therefore, there is a need to develop novel and accurate alternative methods for 
assessing hazard risks and potential potencies of sensitizing chemicals (Divkovic et al., 
2005). Several contact sensitizers, known to cause hypersensitivity responses, have been 
shown to directly induce DC maturation in vitro (Arrighi et al., 2001). Researchers have 
focused on identifying reliable cytokine or phenotypic biomarkers in DCs which could 
function as a predictive test to assess the sensitization potential of a chemical. A range of 
potential biomarkers have been reported including maturation markers; CD86, Major 
Histocompatibility Complex-II (MHC II), CXCR4 (fusin), generation of interleukin (IL)-8, 
intracellular IL-1, mRNA of MCP-1 (Monocyte chemoattractant protein 1)and intracellular 
signalling components (Coutant et al., 1999). However, despite promising data there are 
technical issues for the routine use of these cells such as donor variability, low cell numbers 
and availability of human blood (Rougier et al., 2000). To avoid such issues, human cell 
lines, with characteristics similar to DCs, such as THP-1 and MUTZ-3 cells have been 
utilised (Sakaguchi et al., 2009). MUTZ-3 comprises the most physiologically similar cell 
line to its in vivo DC counterpart and represents the immortalised equivalent of CD34+ DC 
precursors (Larsson et al., 2006). Current assay development utilises a test panel of chemicals 
consisting of extreme, strong, intermediate and weak sensitizers with non-sensitizers all of 
which have been classified by the local lymph node assay (LLNA) in order to correlate in 
vitro data with known in vivo data. When exposed to weak, moderate and strong haptens such 
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as dinitrochlorobenzene (DNCB), MUTZ-3 cells respond by up-regulating phenotypic 
expression of CD40, CD54 and CD86 (Azam et al., 2006). However, although CD86, a key 
costimulatory receptor which activates T cells, appears a promising biomarker, the response 
varies according to the sensitizer and cell type utilised. This reinforces the view that 
integrated multiple in vitro assays are required in order to provide an accurate and robust 
sensitization model (Jowsey et al., 2006). Two new members of the B7 family have been 
identified; programmed death ligand-1 (PDL-1) and PDL-2 which comprise ligands for the T 
cell expressed programmed death receptor-1 (PD-1) (Matsumoto et al., 2004). Several groups 
have independently revealed dual functions of PDL-1 in regulating T cell responses (Kuipers 
et al., 2006). Firstly, PDL-1 signals negatively regulate activated T cell function and survival 
(Freeman et al., 2000). Secondly, PDL-1 signals are able to co-stimulate early T cell priming 
and differentiation in vivo and in vitro (Dong et al., 1999). Thus PDL-1 may be a 
hypothesised to be a putative biomarker for DC-induced sensitisation. 
The sensitizer-specific secretion of cytokines may comprise additional markers for inclusion 
in a combined in vitro assay. Researchers have identified a number of cytokines of 
importance in the sensitization process which may constitute an important aspect of in vitro 
test development. Recent studies suggested that IL-8 detection following sensitizer or non-
sensitizer application to THP-1 cells could function as a promising in vitro model to assist 
with sensitization screening (Mitjans et al., 2008, Miyazawa et al., 2008, Toebak et al., 2006). 
In addition, IL-18 has also been proposed as a relevant biomarker (Wang et al., 2002). Thus, 
the current study used cytokine array technology to identify a sensitizer-specific profile in 
moDCs and MUTZ cells.  
Currently, it is thought that no single in vitro assay will meet all the necessary requirements 
and assays consisting of multiple biomarkers should be developed for use concurrently. The 
aim of this study, therefore, was to identify novel biomarkers which may aid in vitro assay 
development.  
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2. Materials and Methods. 
2.1. Chemical compounds. 
The skin sensitizers Dinitrochlorobenzene (DNCB), Eugenol (E), Isoeugenol (IE), P- 
Phenylenediamine (PPD) and the non-sensitizer Salicyclic Acid (SA) were dissolved in 
dimethyl sulphoxide (DMSO) (Sigma Aldrich, UK).  The skin sensitizer Cinnamaldehyde 
(Cin) and the non-sensitizer Sodium Lauryl Sulphate (SLS) were dissolved in the appropriate 
cell culture medium. All chemicals were supplied by the EU Framework VI Sens-It-Iv 
Consortium (LSHP-CT-2006-018681). 
 
2.2. Cell culture. 
MUTZ-3, a human acute myeloid leukaemia cell line was obtained from DSMZ (Germany). 
MUTZ-3 cells were cultured in -MEM medium (including ribonucleosides, 
deoxyribonucleosides [Fisher Scientific, UK]) supplemented with 20% Foetal Calf Serum 
(Invitrogen, UK), 100U/ml and 100µg/ml Penicillin/Streptomycin solution, 2mM L-
Glutamine (Fisher Scientific, UK) and 10ng/ml rhGM-CSF (Peprotech EC, UK). Twice 
weekly cells were harvested and re-cultured at 2x105/ml. 
 
2.3. Generation of monocyte derived DC (moDCs). 
All experiments were carried out in accordance with local ethical guidelines.  Peripheral 
blood mononuclear cells (PBMCs) were isolated from fresh peripheral blood, from healthy 
volunteers, by density centrifugation. PBMCs, present in the buffy layer, were aspirated and 
washed (x3) in sterile PBS. Monocytes were isolated from the PBMC population using the 
Monocyte Isolation Kit II (Miltenyi Biotec, Germany) according to the manufacturer’s 
instructions and subsequently cultured following an established method (Zheng et al., 2004). 
Briefly, cells were cultured at 2x106/ml at 37°C, 5%CO2 for 5 days in RPMI-1640 (Fisher 
Scientific, UK) supplemented with 10% FCS, 100U/ml and 100µg/ml 
Penicillin/Streptomycin solution and L-Glutamine (2mM) in the presence of GM-CSF 
(800U/ml) and IL-4 (500U/ml [Peprotech EC, UK]). Cells were fed every other day through 
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the replenishment of half the volume of fresh medium and cytokines.  At day 5, cells were 
characterised and considered to be iDC by the low expression of CD14, CD40, CD80, CD86 
and CD83 (Williams et al., 2008).  
 
2.4. Optimisation of concentration ranges used. 
MoDCs and MUTZ-3 cells were seeded at 1x106 cells/well and incubated in 24 well plates 
with appropriate concentrations of the sensitizers and non-sensitizers for 24 hours prior to 
phenotypic analysis. Cell supernatants were also harvested for cytokine analysis. To 
determine the maximum sensitizer concentration for cell application, a dose-response study 
was performed, in which both cell types were exposed to a range of concentrations to ensure 
maximum cell death did not exceed 25%. Cell viability was determined by propidium iodide 
(PI) staining (20µg/ml [Sigma Aldrich, UK]) and evaluated by flow cytometry. The solvents 
and concentrations of the sensitizers/non-sensitizers utilised within this study are listed in 
Table 1. 
 
2.5. Immunophenotyping of moDCs and MUTZ-3 cells. 
Following 24 hours incubation, cells were harvested and stained for flow cytometric analysis. 
Cells were washed and re-suspended in 50µl of either control medium, CD14 (5µl purified 
antibody in 0.01M PBS containing 1% BSA and 15mM sodium azide [Sigma Aldrich, UK]), 
CD34 (0.5µg/ml), CD80 (0.5µg/ml), CD86 (4µg/ml [BD Biosciences, UK]) or PDL-1 
(5µg/ml [Insight Biotech, UK]) and incubated for 30 min at 4°C. Cells were washed and 
incubated with 50µl polyvalent anti-mouse IgG FITC antibody (Sigma Aldrich, UK) for 30 
minutes at 4°C. Phenotypic expression was analysed using the BD FACSVantage and BD 
CellQuest software.  Cells were gated against FSC/SSC and 10,000 events collected. 
Geometric mean fluorescence intensity (GMFI) changes from isotype control were assessed 
and mean + SEM presented.  
 
2.6. Determination of MCP-1 and RANTES secretion. 
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Cell supernatants were harvested following 24 hour exposure of moDCs and MUTZ-3 cells 
to the sensitizers and non-sensitizers in complete medium. Cytokine array analysis was 
performed in triplicate from three independent repeats by Millipore, UK. Results are 
demonstrated as mean pg/ml.  
 
2.7. Statistical Analysis. 
All data has been expressed as the mean ± SEM.  Data was statistically analysed using a two 
sample student’s t test where P values 0.05 were considered as significant. Cells treated with 
sensitizers which were prepared in medium are compared to the untreated cell control and 
those prepared in DMSO are compared to the DMSO cell control.  
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3. Results. 
3.1. CD86 expression on MUTZ-3 cells and moDCs. 
 
Firstly, the key identification markers of MUTZ-3 cells; CD14, CD34, CD80 and CD86, 
were analysed by flow cytometry to confirm the presence of a progenitor MUTZ-3 
population. Phenotypic analyses indicated a typical MUTZ-3 progenitor phenotype 
comprising moderate levels of CD14 (33±1.8%), high levels of CD34 (62±0.8%) with lower 
expression of CD80 (2±0.8%) and CD86 (19±1.5%) (data not shown).       
In this study, CD86 expression was studied to further investigate and validate this marker as a 
sensitization biomarker but most importantly CD86 expression was used as a comparative 
tool to assess the novel biomarker PDL-1. When compared to basal expression of the 
appropriate control, CD86 was highly significantly up-regulated on MUTZ-3 cells in 
response to all concentrations tested of DNCB, Cin and PPD (Fig. 1). DNCB and PPD 
application induced a dose-dependent CD86 up-regulation with Cin consistently up-regulated 
in all tested concentrations. Modulation of CD86 was not observed following treatment with 
the non-sensitizers SLS and SA, therefore, confirming the usefulness of CD86 as a 
sensitization biomarker. 
Figure 2 demonstrated that moDC-expressed CD86 was up-regulated consistently and 
significantly in response to DNCB (5µM) and E (900, 920µM) application when compared 
with the DMSO control. No significant modulation of CD86 expression on moDCs occurred 
following exposure to Cin and IE or to the non-sensitizers, SLS and SA thus demonstrating a 
specific up-regulation of CD86 in response to some sensitizers. 
 
3.2. Investigating the expression of PDL-1 as a novel sensitization biomarker in MUTZ-3 
cells and moDCs. 
To evaluate PDL-1 as a biomarker of sensitization, firstly, MUTZ-3 cells were exposed to a 
panel of sensitizers and non-sensitizers. As demonstrated in figure 3, treatment of MUTZ-3 
with DNCB (5µM), Cin (50, 75, 100µM), IE (930, 970µM) and PPD (150, 200µM) 
significantly up-regulated PDL-1 expression above basal expression on the untreated and 
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DMSO treated controls, although no dose-related effect was observed. There were no 
changes following SLS or SA treatment, therefore, PDL-1 was predominantly sensitizer-
specific and demonstrates potential as a novel biomarker of sensitization.   
In order to verify PDL-1 as a potential tool for discriminating between sensitizers and non-
sensitizers, modulations of PDL-1 expression was further investigated in moDCs. The 
expression of PDL-1 was significantly up-regulated in response to Cin (90, 120µM), IE (950, 
970µM) and E (900, 920µM) when compared to basal expression of the appropriate control. 
No significant changes were observed upon DNCB and PPD treatment of moDCs. Non-
sensitizers, SLS and SA, did not influence the levels of PDL-1 from the basal expression of 
the controls as illustrated in figure 4. 
 
3.3. MCP-1 and RANTES secretion from MUTZ-3 cells and moDCs following sensitizer 
exposure. 
This study also addressed the detection of soluble factors secreted from MUTZ-3 cells and 
moDCs as possible novel biomarkers. Resulting from initial cytokine microarray analyses, 
two cytokines, MCP-1 and RANTES, were selected for further evaluation (Table. 2). As 
demonstrated in figure 5a the secretion of MCP-1 from MUTZ-3 cells upon sensitizer and 
non-sensitizer treatment was very inconsistent and as such the use of MCP-1 is neither 
reliable nor robust in predicting sensitization in MUTZ-3 cells. The secretion of RANTES, 
however, may present a potentially useful biomarker for detecting DNCB and Cin 
sensitization. In response to these sensitizers, RANTES secretion was significantly modulated 
when compared to the respective controls (Fig. 5b).    
MCP-1 secretion from moDCs was significantly reduced in response to DNCB (8µM), E 
(900µM) and IE (950µM) treatment for 24 hours. The application of Cin, PPD and the non-
sensitizer, SLS, did not induce a change from basal MCP-1 levels secreted by moDCs (Fig. 
6a). However, no significant differences were observed in RANTES secretion with any of the 
sensitizers or non-sensitizer tested when compared with basal moDC secretion (Fig. 6b).  
 
4. Discussion. 
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The development and validation of novel in vitro methods for assessing the potential of 
chemicals to cause allergic sensitization is of ultimate importance in reducing animal tests 
and maintaining product safety. Predictive testing to assess the ability of chemicals to induce 
ACD is a major part of the safety assessments performed on new ingredients in topically 
applied cosmetics and drugs (Ashikaga et al., 2002). The main research objectives of the 
current study were, therefore, to identify novel biomarkers to evaluate the sensitization 
predictability of a chemical. Previous research has demonstrated that chemical allergens, such 
as DNCB, can induce changes in the expression of DC surface markers including CD54, 
CD80 and CD86, suggesting that phenotypic analyses could constitute the basis for an in 
vitro predictive test (Hulette et al., 2002). Cytokine analyses also indicated that following 
allergen treatment there were modifications in cytokine production (Aiba et al., 1997). The 
current research, therefore, aimed to further validate CD86 as a sensitization biomarker and 
evaluate the effects of contact sensitizer and non-sensitizer application on the phenotypic 
expression of PDL-1 and secretion of MCP-1 and RANTES from moDCs and the DC-like 
cell line MUTZ-3 as potentially novel biomarkers for inclusion in in vitro sensitization 
assays.  
It has been frequently documented that in vitro use of DCs are associated with research 
limitations such as inter-donor variability (Ryan et al., 2005). As a consequence of these 
limitations, research is currently focusing on the development of DC-like cell lines, which 
display characteristics similar to their in vivo counterparts (Ashikaga et al., 2002). In the 
current research, the myelomonocytic cell line, MUTZ-3, was assessed for the ability to 
respond to sensitizing agents and the expression of biomarkers investigated. When compared 
to other DC-like cell lines used in current research, such as THP-1 cells, MUTZ-3 represent 
the most physiologically similar cells to in vivo DCs (Larsson et al., 2006).  
Firstly, the response of the classic co-stimulatory marker, CD86, was analysed on MUTZ-3 
cells and moDCs. Myriad reports have highlighted CD86 as a suitable marker for developing 
an in vitro test system (Aiba et al., 1997; Tuschl and Kovac, 2001; De Smedt et al., 2002; 
Aeby et al., 2004; Boisleve et al., 2004; Sakaguchi et al., 2006; Pepin et al., 2007), although 
Hulette et al. (2005) reported that CD86 was an unreliable biomarker in primary DCs due to 
differences in donor variability and responsiveness. In contrast to these findings, in the 
present study, CD86 was found to be consistently and specifically up-regulated on MUTZ-3 
cells in response to DNCB, Cin and PPD, although, moDCs only showed a response to the 
sensitizers DNCB and E. Thus, although CD86 may be a useful biomarker, marked 
ACCEPTED MANUSCRIPT 
differences were observed in the phenotypic responses to the sensitizers between the two cell 
types. Sakaguchi et al. (2006) also observed variable responses depending on both the 
sensitizer and cell type used suggesting that sensitizers act differently depending on the 
cellular system (Sakaguchi et al., 2006). Recent work has indicated that the cell 
responsiveness to sensitizers is affected by external ‘danger signals’ (Lavergne et al., 2009) 
and hapten:protein interactions (Jenkinson et al., 2009) thus there are a range of factors which 
impact on overall predictability of DCs to sensitizers in in vitro culture. Overall, CD86 does 
respond specifically to certain sensitizers but clearly does not act as a strong predictive 
biomarker thus new biomarkers are required to extend the predictability of a mono-cell 
culture in vitro test. Recently identified markers eg. PDL-1, expressed on DCs, have been 
characterised as belonging to the B7 receptor family, which includes CD86. PDL-1 comprises 
the ligand for the T cell expressed PD-1 receptor and is of importance in regulating the 
balance between T cell activation, tolerance and immunopathology (Keir et al., 2008). 
Therefore, the phenotypic response of PDL-1 to sensitizers and non-sensitizers was 
investigated on MUTZ-3 cells and moDCs. PDL-1 proved a promising sensitization 
biomarker in MUTZ-3 cells where sensitizer-specific modulation of PDL-1 occurred in 
response to DNCB, Cin, IE and PPD. In addition, moDC expressed PDL-1 was specifically 
up-regulated in response to the sensitizers Cin, IE and E. Intriguingly, no response was 
observed with DNCB. Further work by us (unpublished data) suggests that this outcome may 
have a functional underpinning as T cell proliferation studies with sensitiser (DNCB, Cin, E, 
IE and PPD)-induced DC’s only showed a significantly increased proliferation in response to 
DNCB thus suggesting that DNCB induces a strongly stimulatory T cell outcome and thus 
may not upregulate the inhibitory PDL-1. Thus, as previously observed, a difference in the 
response of PDL-1 was evident between cell types, however, PDL-1 showed a better 
predictability of sensitizer exposure than CD86. PDL-1 has been previously reported to be 
induced on DCs through sensitizer exposure in vivo (Kim et al., 2006) and thus is a good 
candidate as a novel biomarker in MUTZ-3 cells.  
Phenotypic markers comprise only one source from which to discover novel sensitization 
biomarkers. The current research also addressed the detection of soluble factors secreted from 
MUTZ-3 cells and moDCs. The secretion of cytokines and chemokines from DCs and 
MUTZ-3, upon antigenic challenge, is a key factor in the initiation of the immune response 
(Cumberbatch et al., 2005). Supernatants were collected following sensitizer/non-sensitizer 
exposure and tested for a range of cytokines and chemokines (IL-12, IL-15, IL-1, IL-7, IP-
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10, MCP-1, MIP-1, TNF-, RANTES) which had been documented to be of importance in 
the sensitization process. Following these initial studies, MCP-1 and RANTES were further 
investigated for their potential to act as useful, accurate and reliable biomarkers.  
Analysis of the secretion of MCP-1 from sensitizer-exposed MUTZ-3 cells revealed no 
consistent change from solvent control or irritant control, therefore, negating the use of MCP-
1 as a sensitization biomarker in MUTZ-3 cells. However, moDCs showed a specific 
decrease in MCP-1 for all sensitizers tested except PPD. The reduction in MCP-1 secretion 
levels does not appear to be logical in the context of a sensitization immune response, as even 
during the initial sensitization phase, increased numbers of DCs and other APCs are recruited 
to interact with the allergen, mature and migrate to the lymph nodes for T cell presentation 
and activation. However, with regards to moDCs, it may be possible that the MCP-1 effects 
illustrated in the current study may not have a functional role. It appears possible that the 
expression of MCP-1 may have peaked at an earlier time point than that investigated within 
this study. Published research has shown, albeit from various cell lines, that upon stimulation 
with TNF- or IL-1, MCP-1 was detectable at 4 hours following stimulation with maximal 
secretion observed around 8 hours post stimulation. Levels had decreased significantly by 24 
hours (Goldstein et al., 1996; Pype et al., 1999). Therefore, with regards to moDC MCP-1 
secretion, optimisation of the time point for maximal detection may be required.  
Studies of cytokine secretion from MUTZ-3 cells demonstrated that RANTES secretion was 
significantly and consistently increased in response to both DNCB and Cin, although no 
change in E, IE and PPD was observed. However, the latter results may be related to the 
metabolic factors highlighted previously reducing the sensitizer capacity of these pro-
haptens. The effects of Octanoic Acid and Oxazolone on MUTZ-3-secretion of RANTES has 
also been investigated and significant increases above irritant controls (Glycerol and Lactic 
acid [data not shown] were found thus RANTES does appear a novel biomarker on MUTZ-3 
cells. However, this outcome is not seen in moDCs where no significant changes from irritant 
or solvent control was observed. RANTES has been previously identified in vivo as being a 
key cytokine in the murine ear test to DNCB (Baumer et al., 2004) thus supporting its 
relevance as an in vitro biomarker. In order to compare the sensitizer predictability of 
RANTES with a currently used cytokine (Mitjans et al., 2008, Toebak et al., 2006, Miyazawa 
et al., 2008) we investigated the generation of IL-8 on MUTZ-3 cells. Our unpublished data 
showed that IL-8 was increased comparably to the sensitizers seen for RANTES, thus, 
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RANTES can be considered as extending the in vitro biomarkers available for sensitizer 
testing. 
Many investigations are currently underway to develop in vitro sensitization assays and novel 
biomarkers resulting from phenotypic, cytokine, genomic and proteomic studies are being 
revealed. It is difficult to envisage that an accurate single in vitro method of prediction could 
be developed as many factors contribute to the manifestation of ACD such as chemical 
structure, binding affinity and immune responsiveness. It is likely that combined multiple 
tests which correlates with known in vivo data derived from the LLNA and human data is the 
most likely direction in which research will focus. Our findings, amongst others, clearly 
demonstrates large variation in the expression of phenotypic or cytokine markers, therefore, 
highlighting that biomarker responses in moDCs or MUTZ-3 is not consistent or sensitizer 
specific in all cases which further strengthens the case for development of an in vitro assay 
comprising multiple biomarkers to ensure strong and reliable predictability. This research has 
demonstrated novel phenotypic and chemokine biomarkers of MUTZ-3 cells which will be a 
useful addition to further in vitro sensitization research.     
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Figure 1. Modulation of CD86 expression on MUTZ-3 cells following treatment with 
sensitizers and non-sensitizers. a. CD86 was highly significantly up-regulated on MUTZ-3 
cells in response to all concentrations tested of DNCB, Cin and PPD. There was no change 
from basal levels following treatment with the non-sensitizers, SLS and SA. Data is 
expressed as GMFI ± SEM. n3. **p<0.01, ***p<0.001 compared to the DMSO control. xxx 
p<0.001 compared to the untreated cells. b. CD86 expression by MUTZ-3 cells with grey 
overlay demonstrating CD86 up-regulation in response to DNCB (8µM) c. in response to Cin 
(100µM) and d. in response to PPD (200µM). The shaded histogram depicts the appropriate 
control cells stained with CD86. One representative histogram of n3 is shown.                                                                  
 
 
Figure 2. Modulation of CD86 expression on moDCs. a. moDC-expressed CD86 was up-
regulated significantly in response to DNCB (5µM) and E (900, 920µM) application when 
compared with the DMSO control. The non-sensitizers, SLS and SA, did not increase CD86 
expression above basal levels. Data is expressed as GMFI ± SEM. n3. *p<0.05 compared to 
the DMSO control. b. CD86 expression by moDCs with grey overlay demonstrating CD86 
up-regulation in response to DNCB (5µM) and c. in response to E application (920µM). The 
shaded histogram depicts the appropriate control cells stained with CD86. One representative 
histogram of n3 is shown. 
 
 
Figure 3. PDL-1 expression as a novel sensitization biomarker in MUTZ-3 cells. a. 
Treatment of MUTZ-3 cells with DNCB (5µM), Cin (50, 75, 100µM), IE (930, 970µM) and 
PPD (150, 200µM) significantly up-regulated the expression of PDL-1 above basal 
expression of the appropriate control. There were no changes following SLS or SA treatment. 
Data is expressed as GMFI ± SEM. n3. *p<0.05 compared to the DMSO control. x p<0.05, 
xx p<0.01 compared to the untreated control. b. PDL-1 expression on MUTZ-3 cells with 
grey overlays demonstrating PDL-1 up-regulation in response to DNCB (5µM) c. in response 
to Cin (100µM), d. in response to IE (970µM) and e. in response to PPD application 
(200µM). The shaded histogram depicts the appropriate control cells stained with PDL-1. 
One representative histogram of n3 is shown.                                  
 
 
Figure 4. PDL-1 expression in moDCs following sensitizer exposure. a. The expression of 
PDL-1 on moDCs was significantly up-regulated in response to Cin (90, 120µM), IE (950, 
970µM) and E (900, 920µM) when compared to basal expression levels. The application of 
SLS and SA did not influence the levels of PDL-1. Data is expressed as GMFI ± SEM. n3. 
*p<0.05, **p<0.01, ***p<0.001 compared to the DMSO control. xxx p<0.001 compared to 
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the untreated control. b. PDL-1 expression on moDCs with grey overlays demonstrating 
PDL-1 up-regulation in response to Cin (120µM) application, c. IE application (970µM). d. E 
application (920µM). The shaded histogram depicts the appropriate control cells stained with 
PDL-1. One representative histogram of n3 is shown. 
Figure 5. MCP-1 and RANTES secretion from MUTZ-3 cells. a. MCP-1 secretion from 
MUTZ-3 cells was inconsistent following sensitizer application. b. Exposure of MUTZ-3 
cells to DNCB (10µM) and Cin (100µM) significantly increased RANTES secretion when 
compared with the appropriate control. Other sensitizers and non-sensitizers tested did not 
influence the secretion of RANTES from MUTZ-3 cells. Data is expressed as mean pg/ml ± 
SEM. n=3 in triplicate. *p<0.05, **p<0.01, ***p<0.001 when compared with the DMSO 
control. x p<0.05 compared with the untreated cell control.                                        
 
 
Figure 6. Cytokine response of moDCs. a. MCP-1 analysis revealed significantly reduced 
secretion specific to DNCB (8µM), E (900µM) and IE (950µM). MCP-1 secretion was not 
modulated by the application of Cin or PPD. b. RANTES secretion from moDCs in response 
to sensitizers. There were no significant changes in the secretion of RANTES upon treatment 
of moDCs with either sensitizer or non-sensitizer application. Data is expressed as mean 
pg/ml ± SEM. n=3 in triplicate. *p<0.05 when compared with the DMSO control.  
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Table 1. Range of sensitizer/non-sensitizer concentrations and solvents utilised.  
 
 
 
Sensitizers/non-
sensitizers 
moDCs MUTZ-3 
 
Solvent 
DNCB 5, 8µM 5, 8, 10µM DMSOa 
Cin 90, 120µM 50, 75, 100µM Medium 
IE 950, 970µM 930, 970µM DMSOa 
E 900, 920µM 880, 900, 920µM DMSOa 
PPD 150, 200µM 150, 200µM DMSOa 
SA 50µM 50µM DMSOa 
SLS 300µM 300µM Medium 
 
    
a
 cells exposed to a final concentration of 0.1% DMSO. 
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Cell type 
 
 
IL-12 
 
IL-15 
 
IL-1 
 
IL-7 
 
MCP-1 
 
MIP-1 
 
TNF- 
 
RANTES 
 
IP-10 
DC + DMSO 12.2 nd nd 2.8 214.5 32.9 46.4 2300.0 1630.0 
DC + DNCB 8µM nd nd nd 7.8 133.5 35.6 14.5 465.0 nd 
DC + Cin 120µM nd nd nd 4.7 79.0 29.1 7.2 465.0 2.11 
DC + SLS 300µM nd nd nd 4.7 106.1 161.5 22.4 345.5 5.4 
MUTZ + DMSO 3.58 nd nd 6.68 1555.0 14.4 nd 270.0 2.63 
MUTZ + DNCB 10µM 6.07 nd 1.3 9.0 3110.0 23.3 0.1 203 1.17 
MUTZ + Cin100µM 3.58 1.29 1.5 9.9 815.5 20.4 nd 369.5 nd 
 
Cytokines = pg/ml 
nd: Both replicates below detectable limits. 
 
 
Table 2. Cytokine profile of MUTZ-3 and moDCs in response to sensitizer and non-sensitizer application. Exposure of MUTZ-3 cells 
induced MCP-1 and RANTES secretion only. Of all cytokines investigated predominant secretion of MCP-1 and RANTES was observed 
from moDCs. Data is expressed as mean pg/ml. n=1 in duplicate. 
 
